Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer

Cancer Chemother Pharmacol. 2015 Feb;75(2):255-62. doi: 10.1007/s00280-014-2622-6. Epub 2014 Nov 27.

Abstract

Purpose: To investigate the role of preoperative neutrophil-to-lymphocyte ratio (NLR) in prediction of response to first-line platinum-based chemotherapy and survival outcome in serous ovarian cancer (SOC) patients.

Methods: Clinicopathologic data were reviewed for patients with SOC treated with primary cytoreduction followed by platinum-based chemotherapy. The correlations of NLR value with clinicopathological features, clinical response to chemotherapy, and survival outcome were further explored.

Results: High preoperative NLR was significantly associated with advanced FIGO stage, histological grade, increased serum CA-125 level, and positive lymph node metastasis (P < 0.05, respectively). SOC patients in the third and fourth NLR quartile had significantly lower complete response rates compared to those in the first NLR quartile. In addition, survival analysis identified NLR as an independent prognostic factor for both PFS (HR 2.262, 95% CI 1.342-3.811; P = 0.002) and OS (HR 3.254, 95% CI 1.741-6.084; P < 0.001) in SOC patients.

Conclusions: Our findings indicated that high levels of preoperative NLR might be a potential biomarker of worse response to first-line platinum-based chemotherapy and poor clinical outcomes in patients with SOC. Further validation of this easily available parameter as a potential stratification tool in prospective studies should be encouraged.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphocyte Count*
  • Middle Aged
  • Neutrophils*
  • Organoplatinum Compounds / therapeutic use*
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / surgery
  • Predictive Value of Tests
  • Preoperative Period
  • Prognosis
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds